2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Prostate Cancer

Impact of a Rash Management Guide in Patients Receiving Apalutamide for High-Risk Localized Prostate Cancer in the Apa-RP Study - Beyond the Abstract

Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes.

Impact of a Rash Management Guide in Patients Receiving Apalutamide for High-Risk Localized Prostate Cancer in the Apa-RP Study - Beyond the Abstract



  • Jason Hafron, MD, CMO, Oncologist, Director of Research, Michigan Institute of Urology, MI
  • Neal Shore, MD, FACS, Director, CPI (Certified Principal Investigator by the Association of Clinical Research Professionals), Medical Director for the Carolina Urologic Research Center, AUC Urology Specialists, Myrtle Beach, South Carolina
Read the Abstract